In a note on July 14, SVB Leerink analyst Geoffrey Porges argued that the company needs to revamp its capital allocation strategy, and that its approach to acquisitions isnâ€™t working.Write to Josh Nathan-Kazis at josh.nathan-kazis@barrons.com The biopharmaceutical sector has slightly outperformed the broader market this past year, with the S&P 500 Pharmaceutical, Biotech & Life Sciences index up 4.